Sensitivity to cholecystokinin-tetrapeptide in major depression

Journal of Affective Disorders

Volumn 80, Issue 2-3, 2004, Pages 285-290

  Koszycki, Diana ^a   Copen, John ^a   Bradwejn, Jacques ^a  

^a ROYAL OTTAWA HOSPITAL   (Canada)

Author keywords

CCK 4; Cholecystokinin; Major depression; Panic attacks; Panic disorder

Indexed keywords

PLACEBO; TETRAGASTRIN;

ADULT; ANAMNESIS; ARTICLE; BEHAVIOR; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG SCREENING; DRUG SENSITIVITY; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MENTAL PATIENT; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SYMPTOM;

ADULT; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PANIC DISORDER; QUESTIONNAIRES; RECEPTORS, DRUG; SEVERITY OF ILLNESS INDEX; TETRAGASTRIN;

EID: 2342576775     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(03)00110-1     Document Type: Article

References (13)

1. Akiyoshi J., Isogawa K., Tsutsumi T., Kasturagi S., Kohno K., Furuta M., Yamamoto Y., Yamada K., Fujji J. Cholecystokinin tetrapeptide-induced calcium mobilization in T cells of patients with panic disorder, major depression or schizophrenia. Biol. Psychiatry. 42:1997;151-154
2. Bradwejn J., Koszycki D. The cholecystokinin hypothesis of anxiety and panic disorders. Ann. NY Acad. Sci. 713:1994;273-282
3. Brambilla F., Bellodi L., Perna G., Garberi A., Panerai A., Cacerdote P. Lymphocyte cholecystokinin concentrations in panic disorder. Am. J. Psychiatry. 150:1993;1111-1113
4. Geracioti T.D., Nicholson W.E., Orth D.N., Ekhator N.N., Loosen P.T. Cholecystokinin in human cerebrospinal fluid: concentrations, dynamics, molecular forms and relationship to fasting and feeding in health, depression and alcoholism. Brain Res. 629:1993;260-268
5. Gerner R.H., Yamada T. Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. Brain Res. 238:1982;298-302
6. 2 inhalation in panic disorder: a comparison with major depression and premenstrual dysphoric disorder. Am. J. Psychiatry. 158:2001;58-67
7. Le Melledo J.-M., Merani S., Koszycki D., Bellavance F., Palmour R., Gutkowska J., Steinberg S., Bichet D.G., Bradwejn J. Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phases. Neuropsychopharmacology. 20:1999;81-91
8. Löfberg C., Agren H., Harro J., Oreland L. Cholecystokinin in CSF from depressed patients. Possible relations to severity of depression and suicidal behavior. Eur. Neuropsychopharmacol. 8:1998;153-157
9. Lydiard R.B., Ballenger J., Laraia M., Fossey M.D., Beinfeld M.C. CSF cholecystokinin concentrations in patients with panic disorder and normal comparison subjects. Am. J. Psychiatry. 149:1992;691-693
10. McGrath P.J., Stewart J.W., Liebowitz M.R., Markowitz J.M., Quitkin F.M., Klein D.F., Gorman J.M. Lactate provocation of panic attacks in depressed outpatients. Psychiatry Res. 25:1988;41-47
11. 2 challenge in panic and mood disorders. J. Affect. Disord. 33:1995;189-194
12. Swain J., Koszycki D., Shlik J., Bradwejn J. Pharmacological challenge agents in anxiety. Nutt D., Ballenger J. Anxiety Disorders. 2003;269-296 Blackwell, Oxford
13. Targum S.T. Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder. Biol. Psychiatry. 28:1990;21-34